CHARACTERIZATION OF PK/PD OF ANIFROLUMAB IN PATIENTS WITH MODERATE TO SEVERE SLE

被引：3

作者：

Chia, Y. L. ^{[1
]}

Tummala, R. ^{[2
]}

Mai, T. ^{[3
,4
]}

Rouse, T.

White, W. ^{[2
]}

Morand, E. F. ^{[5
]}

Furie, R. ^{[6
]}

机构：

[1] AstraZeneca, BioPharmaceut R&D, San Francisco, CA USA

[2] AstraZeneca, BioPharmaceut R&D, Gaithersburg, MD USA

[3] Genentech Inc, Clin Pharmacol & Modeling & Simulat, San Francisco, CA USA

[4] AstraZeneca, BioPharmaceut R&D, Gothenburg, Sweden

[5] Monash Univ, Ctr Inflammatory Dis Monash Hlth, Melbourne, Vic, Australia

[6] Zucker Sch Med Hofstra Northwell, Div Rheumatol, Great Neck, NY USA

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2021年 / 80卷

关键词：

D O I：

10.1136/annrheumdis-2021-eular.1464

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

POS0688

引用

页码：590 / 591

页数：2

共 4 条

[1] Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus [J].

Furie, Richard ;

Khamashta, Munther ;

Merrill, Joan T. ;

Werth, Victoria P. ;

Kalunian, Kenneth ;

Brohawn, Philip ;

Illei, Gabor G. ;

Drappa, Jorn ;

Wang, Liangwei ;

Yoo, Stephen .

ARTHRITIS & RHEUMATOLOGY, 2017, 69 (02) :376-386

[2] Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1) a randomised, controlled, phase 3 trial [J].

Furie, Richard A. ;

Morand, Eric F. ;

Bruce, Ian N. ;

Manzi, Susan ;

Kalunian, Kenneth C. ;

Vital, Edward M. ;

Ford, Theresa Lawrence ;

Gupta, Ramesh ;

Hiepe, Falk ;

Santiago, Mittermayer ;

Brohawn, Philip Z. ;

Berglind, Anna ;

Tummala, Raj .

LANCET RHEUMATOLOGY, 2019, 1 (04) :E208-E219

[3]

Kuruvilla D., 2020, AAPS, V360

[4] Trial of Anifrolumab in Active Systemic Lupus Erythematosus [J].

Morand, Eric F. ;

Furie, Richard ;

Tanaka, Yoshiya ;

Bruce, Ian N. ;

Askanase, Anca D. ;

Richez, Christophe ;

Bae, Sang-Cheol ;

Brohawn, Philip Z. ;

Pineda, Lilia ;

Berglind, Anna ;

Tummala, Raj .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (03) :211-221

← 1 →